Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
Posted 14 May 2013 | By Alexander Gaffney, RAC,
The National Association of Attorneys General, an organization comprised of all state attorneys general, has sent a letter to US Food and Drug Administration (FDA) Commissioner Margaret Hamburg asking her to add a black box warning to all narcotic analgesics in the hopes of reducing risks to newborn children.
At issue for the 43 signatories of the letter is the potential for opioid abuse by pregnant women to lead to Neonatal Abstinence Syndrome (NAS), a syndrome that occurs when infants are suddenly cut off from their existing supply of opioids, which were found in the mother's blood and supplied to the fetus through the umbilical cord.
Side effects can be severe and even deadly, and include tremors, vomiting, seizures, weight loss, irritability, hyperactivity, failure to put on weight and other autonomic nervous system disorders.
Worse, the attorneys note that, "There is still sparse scientific data as to optimal treatments for NAS in either the ante or post-partum settings," leaving doctors with few good options with which to treat affected neonates.
The officials continue that regulators should require the use of a "black box warning" for all opioid analgesics in the hopes of making patients aware of the serious risks associated with opioid use and abuse while pregnant.
"Possible content for the warning might be, 'WARNING: Use of Narcotic Analgesics in Pregnant Women May Cause Neonatal Abstinence Syndrome,'" the AGs suggested.
Boxed warnings are frequently required by FDA to ensure that extraordinary risks are conveyed to consumers and are not missed by a patient or physician skimming a label.
For example, in February 2013 FDA announced that prescription codeine products would henceforth be required to contain a boxed warning contraindicating their use in children who have undergone a tonsillectomy procedure. Some children were found to be able to metabolize the drug ultra-rapidly, causing them to overdose and die.
FDA notes three independent scenarios under which it would require a boxed warning:
The letter's request would seem to be aimed at meeting the second of the three standards in that it notes the severity of the adverse reactions and notes the potential benefits of educating consumers. It does not call for a program to ensure safe use of the drug, which is typically contained within a Risk Evaluation and Mitigation Strategies (REMS) program.
The letter does not require or request Hamburg to respond by a particular date.
Tags: Margaret Hamburg, Black Box Warning, Hamburg
Regulatory Focus newsletters
All the biggest regulatory news and happenings.